Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market

Executive Summary

US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.

You may also be interested in...



US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On

Dr Reddy’s can re-launch its generic version of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film in the US following a crucial court ruling that has gone its way. Indivior faces significant turbulence ahead if a generic entry materializes soon.

Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis

Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.

Topics

Related Companies

UsernamePublicRestriction

Register

PS124324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel